Document Detail

Tranexamic acid increases peritoneal ultrafiltration volume in patients on CAPD.
MedLine Citation:
PMID:  10201339     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: The preservation of ultrafiltration (UF) capacity is crucial to maintaining long-term continuous ambulatory peritoneal dialysis (CAPD).The aim of the present study was to investigate whether the antiplasmin agent tranexamic acid (TNA) increases UF volume in CAPD patients. PATIENTS AND METHODS: Fifteen patients on CAPD, 5 with UF loss and 10 without UF loss, were recruited for the study. The effect of TNA was evaluated with respect to changes in UF volume, peritoneal permeability, peritoneal clearance, bradykinin (BK), and tissue plasminogen activator (tPA) concentration. SETTING: Dialysis unit of the Saiseikai Central Hospital. RESULTS: In patients with UF loss, 2 weeks of treatment with oral TNA produced a significant increase in UF volume in all subjects (5/5).TNA also produced a significant increase in peritoneal clearances of urea and creatinine (Cr). However, the peritoneal equilibration test (PET) revealed that TNA had no effect on dialysate/plasma (D/P) Cr, Kt/V, or the protein catabolic rate (PCR).TNA also had no effect on net glucose reabsorption. In contrast, significant decreases in BK and blood tPA concentrations in response to TNA treatment were noted. BK concentration in drainage fluid was also reduced. In the case of patients without UF loss,TNA produced an increase in UF volume in 70% (7/10). However, no differences were found in blood and drainage BK and tPA concentrations between theTNA treatment and nontreatment periods in these patients. A comparison of basal BK and tPA concentration showed that there were no differences in these parameters between patients with UF loss and those without loss of UF. Furthermore,TNA given intraperitoneally to a patient also produced a marked increase in UF volume. CONCLUSION: The present study suggests thatTNA enhances UF volume in patients both with and without UF loss. SinceTNA did not affect peritoneal permeability and glucose reabsorption, the mechanism by which TNA exerts an enhancing action on UF is largely unknown. We speculate that it may be associated with suppression of the BK and/or tPA system, at least in patients with UF loss.
S Kuriyama; M Nakayama; H Tomonari; Y Kawaguchi; T Hosoya
Related Documents :
19776039 - Peritoneal dialysis in brazil: twenty-five years of experience in a single center.
10596989 - Tuberculous peritonitis: analysis of 35 cases.
16362159 - Restoration of peritoneal integrity after withdrawal of peritoneal dialysis: characteri...
10406559 - New solutions for peritoneal dialysis in adult and pediatric patients.
18379549 - Contrasting clinical outcomes between different modes of peritoneal dialysis regimens: ...
12032369 - A pilot study comparing percutaneous decompression with decompressive laparotomy for ac...
9681309 - "not so immediate" hypersensitivity--the danger of biphasic anaphylactic reactions.
12803369 - Role of epidemiologic information system in sudden death prevention among croatia's hae...
23713879 - Clinical uses of 1,25-dihydroxy-19-nor-vitamin d2 (paricalcitol).
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis     Volume:  19     ISSN:  0896-8608     ISO Abbreviation:  Perit Dial Int     Publication Date:    1999 Jan-Feb
Date Detail:
Created Date:  1999-05-24     Completed Date:  1999-05-24     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8904033     Medline TA:  Perit Dial Int     Country:  CANADA    
Other Details:
Languages:  eng     Pagination:  38-44     Citation Subset:  IM    
Division of Nephrology, Saiseikai Central Hospital, Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Antifibrinolytic Agents / administration & dosage,  therapeutic use*
Blood Proteins / metabolism
Bradykinin / analysis,  blood
Creatinine / analysis,  blood
Dialysis Solutions / analysis
Glucose / pharmacokinetics
Injections, Intraperitoneal
Middle Aged
Peritoneal Dialysis, Continuous Ambulatory*
Peritoneum / drug effects*,  metabolism
Permeability / drug effects
Tissue Plasminogen Activator / analysis,  blood
Tranexamic Acid / administration & dosage,  therapeutic use*
Urea / analysis,  blood
Reg. No./Substance:
0/Antifibrinolytic Agents; 0/Blood Proteins; 0/Dialysis Solutions; 1197-18-8/Tranexamic Acid; 50-99-7/Glucose; 57-13-6/Urea; 58-82-2/Bradykinin; 60-27-5/Creatinine; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Frequency and causes of discrepancy between Kt/V and creatinine clearance.
Next Document:  Analysis of the peritoneal equilibration test in Mexico and factors influencing the peritoneal trans...